Search results
Ampligen continues to be evaluated, and as of May 2021 is the subject of phase 2 and phase 3 trials to potentially treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and several cancers. As of 2021, there is limited scientific evidence supporting the therapeutic efficacy of rintatolimod in treating CFS.
14 mar 2012 · Rintatolimod (Ampligen®) used in this study was manufactured in accordance with Good Manufacturing Practice (GMP) and tested under Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) guidelines.
In October 2020, AIM received Institutional Review Board approval for the expansion of the AMP-511 protocol to include patients previously diagnosed with SARS-CoV-2 following clearance of the virus, but who still demonstrate chronic fatigue-like symptoms (Long COVID).
9 lut 2015 · Ampligen (rintatolimod) is an experimental nucleic acid therapeutic in development for the treatment of a variety of chronic diseases and viral disorders. Development timeline for Ampligen Date
11 lis 2022 · In October 2022, an immuno-pharma company known as AIM ImmunoTech received approval from the FDA to start its Phase 2 study to evaluate their Investigational New Drug (IND), Ampligen, as a potential treatment for long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Ampligen is currently being used to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center and AIM has commenced a Phase 2 clinical study in locally advanced pancreatic cancer.
25 sty 2024 · AIM ImmunoTech has gained Netherlands Erasmus Medical Center (Erasmus MC) Ethics Committee authorisation to launch a European site for its Phase II clinical trial of Ampligen (rintatolimod) for locally advanced pancreatic cancer.
